A review of 6 placebo-managed clinical trials with 1,134 complete participants concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) ended up linked to a bigger normal enhancement about the Ashworth scale for spasticity in several sclerosis clients in contrast with placebo, although